AbbVie lowered its full-year adjusted earnings outlook to $13.87 to $14.07 a share, down from a prior forecast of $13.91 to $14.11, to account for its $10.9 billion acquisition of Apogee Therapeutics. The pharmaceutical company said the proposed deal is expected to reduce earnings by 14 cents a share in 2026, though the decline will be partially offset by higher-than-expected earnings so far this year.

AbbVie last month agreed to buy Apogee Therapeutics for about $10.9 billion, bolstering its core immunology franchise. The deal, expected to close in the third quarter, would add Apogee's experimental drug zumilokibart, a potential rival to Dupixent from Regeneron Pharmaceuticals and Sanofi as a treatment for moderate-to-severe atopic dermatitis, the most common form of eczema.

The company logged higher profit and revenue in the recent quarter. Analysts polled by FactSet are looking for $14.06 a share.